Due to the high frequency of FLT3 mutations in adult ETP-ALL [41,88], tyrosine kinase inhibitors (TKI) already tested in FLT3-mutated AML [89,90] have emerged as an attractive treatment option. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.